Top Markets
#1 0G 0G +34.27%
#2 Nockchain Nockchain +23.06%
#3 Axelar Axelar +21.57%
#4 Fake World Assets Fake World Assets +19.15%
#5 Full Moon Full Moon +17.70%
#6 Zora Zora +17.54%
#7 Merlin's Seal BTC Merlin's Seal BTC +16.09%
#8 Notcoin Notcoin +16.06%
#9 ADO Protocol ADO Protocol +15.57%
#10 StonkBroker StonkBroker +15.35%
Coin of the day
0G 0G
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Clasificación en acciones #13175
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Precio por acción
$8.46
Última sincronización: 2026-08-28
Capitalización bursátil
$514.33M
Cambio (1 día)
-2.08%
Cambio (1 año)
128.03%
País
US
Comercio Kyverna Therapeutics, Inc. (KYTX)

Categoría

Healthcare
Ingresos de Kyverna Therapeutics, Inc. (KYTX)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Kyverna Therapeutics, Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Kyverna Therapeutics, Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH